$CLB

Core Laboratories (CLB) will release Q3'26 earnings on October 28. Analysts estimate revenue of $131.87M and EPS of $0.16. Results will be announced after market close.

Core Laboratories (CLB) will release Q3 2026 earnings after market close on October 28, 2026, and host a conference call the next day. CEO Larry Bruno, CFO Chris Hill, and SVP Gwen Gresham will discuss financial and operational results. The webcast and replay will be available on the company's website.

Analysts made several calls on Thursday, including Truist initiating Nebius with a Buy rating and $355 price target, Deutsche Bank initiating Clover Health with a Buy rating and $6 target, and Wells Fargo upgrading Synopsys and Yum Brands. Morgan Stanley initiated Revolution Medicine and upgraded TC Energy and DT Midstream. JPMorgan upgraded Meta to Overweight with an $820 target and reiterated Tesla as Neutral.

Core Laboratories Inc. /DE/ (CLB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. On August 19, 2026, Kwaku Temeng verbally notified the Board of Directors of Core Laboratories Inc. (the “Company”) of his i

Bruno Lawrence (Chairman and CEO) purchased 5,000 shares of Core Laboratories Inc. /DE/ (CLB) at $10.78 on 2026-07-31.

Core Laboratories (NYSE:CLB) reported Q2 CY2026 revenue of $124.6 million, down 4.3% year on year, missing analysts’ sales expectations. Non-GAAP profit was $0.11 per share, 26.9% above consensus. Adjusted EBITDA margin was 11.1% and free cash flow was $3.12 million (2.5% margin). The stock fell 4.2% to $9.45 after the release.

Core Laboratories (NYSE:CLB) reported Q2 2026 revenue of $124.6M, up 2% sequentially but down 4% year over year. Operating income was $9.2M, or $9.4M ex-items. GAAP EPS was $0.13, EPS ex-items $0.11. Free cash flow was $3.1M. The company repurchased 214,712 shares for $2.7M and announced a Q3 dividend.

Core Laboratories Inc. /DE/ (CLB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS SECOND QUARTER 2026 RESULTS: • REVENUE OF $124.6 MILLION, UP 2% SEQUENTIALLY AND DOWN 4% YEAR-OVER-YEAR • OPERATING INCOME OF $9.2 MILLION; EX-ITEMS, $9.4 MILLION, UP 42% SEQUENTIALLY AND DOWN 36% YEAR-OVER-YEAR • GAAP EARNINGS

Core Laboratories (CLB), Excelerate Energy (EE), and Black Stone Minerals (BSM) fell in afternoon trading as WTI crude dropped 2.2% to about $71.88 and Brent slipped below $77. The article links the pullback to profit-taking after U.S. reports of secondary strikes on Iran and Trump saying the ceasefire is over, while tanker traffic through the Strait of Hormuz reportedly continued.

After President Trump said an Iran ceasefire is over and threatened new strikes, oil prices rose and the energy complex gained. Oilfield services stocks moved higher, including Core Laboratories (+3.6%), Liberty Energy (+4.1%), and Valaris (+3.2%). The article notes WTI near $70 and Brent near $74 and highlights Liberty Energy’s volatility and YTD gain.